Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Thyroid Neoplasms 2Paraganglioma, Extra-Adrenal 2Carcinoma, Medullary 2Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Cancer Metastatic 1Pheochromocytoma 1Multiple Endocrine Neoplasia Type 1 1Differentiated Thyroid Cancer (DTC) 1Differentiated Thyroid Cancer 1Carcinoma, Neuroendocrine 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adrenocortical Carcinoma 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1surufatinib 1pembrolizumab 1lenvatinib 1apatinib 1anlotinib 1Sorafenib 1Iodine-131 1Everolimus 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer × lenvatinib × Endocrine × Clear all
NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Massachusetts Eye and Ear Infirmary

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡